Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

About IPC

The IPC Impact

  • Educated 1,500 health care providers who attended IPC virtual symposia

  • Trained another 1,000 clinicians via IPC online continuing medical education programs

  • Provided psoriasis resources, tools and information to 16,000 professionals

  • Provided 85,000 individuals with information on COVID-19 and psoriasis

    About IPC

    Our Strategic Plan

    IPC's plan for advancing  knowledge and enhancing  care for patients with psoriasis.

    About IPC

    2020 Annual Report

    Improving psoriasis care worldwide



    Latest news

    March 30, 2021
    Learn how psoriasis severity is currently measured and why a change is necessary, how IPC organized the Delphi process that was used to redefine severity classification, implications and effects the output has on psoriasis treatment providers and psoriasis patients, and ultimately how patients will benefit from this endeavor.
    March 29, 2021
    Janssen Pharmaceutical Companies of Johnson & Johnson published the long-term data of the third phase of the DISCOVER-2a study.
    March 28, 2021
    Sun Pharmaceutical Industries Inc. announces results from their five-year Phase-3 efficacy and safety clinical trial for ILUMYA®(tildrakizumab-asmn) based on a pooled analysis of the ReSURFACE 1 and ReSURFACE 2 extension.
    March 17, 2021
    Update on the PsoProtect Registry. PsoProtect is a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis. Data set currently includes 1002 cases.
      More News


    We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.